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Abstract
Background: Hypertrophic scars (HS) generally occur after injury to the deep layers of the dermis, resulting in
functional deficiency for patients. Growing evidence has been identified that the supernatant of adipose tissue-
derived stem cells (ADSCs) significantly ameliorates fibrosis of different tissues, but limited attention has been paid
to its efficacy on attenuating skin fibrosis. In this study, we explored the effect and possible mechanism of ADSC-
conditioned medium (ADSC-CM) on HS.
Method: Real-time quantitative polymerase chain reaction (qRT-PCR) and Western blotting were used to detect the
expression of collagen I (Col1), collagen III (Col3), and α-smooth muscle actin (α-SMA) after fibroblasts and cultured
HS tissues were stimulated with ADSC-CM and p38 inhibitor/activator. Immunofluorescence staining was
performed to test the expression of α-SMA. Masson’s trichrome staining, hematoxylin and eosin (H&E) staining,
and immunohistochemistry staining were carried out to assess the histological and pathological change of
collagen in the BALB/c mouse excisional model. All data were analyzed by using SPSS17.0 software. Statistical
analysis was performed by Student’s t tests.
Results: The in vitro and ex vivo study revealed ADSC-CM decreased the expression of Col1, Col3, and α-SMA.
Together, thinner and orderly arranged collagen was manifested in HS tissues cultured with ADSC-CM. Dramatically,
the assessed morphology showed an accelerated healing rate, less collagen deposition, and col1- and col3-positive
cells in the ADSC-CM treated group. Importantly, the protein level of p-p38 was downregulated in a concentration-
dependent manner in HS-derived fibroblasts with ADSC-CM treatment, which further decreased the expression
of p-p38 after the application of its inhibitor, SB203580. SB203580 led to an obvious decline in the expression
of Col1, Col3, and α-SMA in fibroblasts and cultured HS tissues and presented more ordered arrangement and
thinner collagen fibers in BALB/c mice. Lastly, anisomycin, an agonist of p38, upregulated the expression of
fibrotic proteins and revealed more disordered structure and denser collagen fibers.
Conclusion: This study demonstrated that ADSC-CM could decrease collagen deposition and scar formation
in in vitro, ex vivo and in vivo experiments. The regulation of the p38/MAPK signaling pathway played an
important role in the process. The application of ADSC-CM may provide a novel therapeutic strategy for HS
treatment, and the anti-scarring effect can be achieved by inhibition of the p38/MAPK signaling pathway.
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Background
Hypertrophic scars (HS) caused by extensive trauma,
deep burns, and sometimes even standard surgery are
usually characterized by abnormal extracellular matrix
deposition and remodeling [1]. HS can be red, firm,
raised, itchy, and painful, and might give rise to signifi-
cant esthetic disfiguration and functional impairment
for patients [2, 3]. To date, the etiological mechanism
is poorly understood, and few effective and specific
therapeutic approaches are utilized in clinics. In HS
tissues, an obvious signature is that fibroblasts trans-
differentiate into myofibroblasts. Meanwhile, myofibro-
blasts produce extensive extracellular matrix (ECM) that
is characterized by the enrichment of collagen I (Col1)
and collagen III (Col3), which are also the main contract-
ive elements during the wound healing and closely associ-
ated with the expression of α-smooth muscle actin
(α-SMA) [4].
Mesenchymal stem cells (MSCs) have been reported
to prevent the development of tissue fibrosis in mount-
ing experimental or pre-clinical studies [5, 6]. MSC
transplantation could inhibit fibrotic formation, and re-
cover impaired function in heart, liver, and lung tissues
[7–10]. However, little attention has been paid to its role
in attenuating skin fibrosis. Adipose tissue-derived stem
cells (ADSCs) belong to the family of MSCs and have
self-renewal and multi-potent capacities. ADSCs have
been recently recognized as an alternative source of rep-
resentative adult stem cells since adipose tissues are
abundant in the body and can be readily obtained using
simple manipulation. Furthermore, the application of
ADSCs is associated with fewer ethical problems and
lower immunogenicity than that of other stem cell types
[11]. In addition, it has been reported that human
ADSCs maintain their characteristics in rats, pigs, and
other animals [12]. ADSCs are promising in a variety of
anti-fibrosis applications by attenuating collagen depos-
ition, although the mechanisms have not been com-
pletely elucidated [12, 13]. Furthermore, paracrine
signaling is considered as one of the main underlying
mechanisms behind the therapeutic effects of MSCs [8].
Therefore, we performed the following experiment by
using the conditioned medium of ADSCs (ADSC-CM)
to observe the effect on HS. The P38/MAPK signaling
pathway plays an important role in HS fibrosis, which
influences HS formation probably by the mitochondrial
death pathway [14], cell differentiation [15], or the acti-
vation of angiotensin II [16]. In this study, we hypothe-
sized that the anti-fibrosis effect of ADSC-CM could be
achieved by the p38/MAPK signaling pathway.
In this work, we investigated the paracrine effects of
ADSCs on HS-derived fibroblasts (HSFs) in vitro, cul-
tured HS tissues ex vivo, and a mouse excisional model
in vivo, and explored the possible mechanism involved
in the anti-fibrotic properties of ADSC-CM. The in vitro
experiment showed that ADSC-CM decreased collagen
deposition and α-SMA expression in HSFs. Simultan-
eously, the ex vivo study revealed that ADSC-CM treat-
ment improved the structure of collagen and decreased
the protein level of fibrotic markers. Furthermore,
ADSC-CM injection in a mouse excisional model re-
sulted in a significant improvement in skin fibrosis. Fur-
thermore, the expression of p-p38 decreased in a
concentration-dependent manner; after adding p38 in-
hibitor, the levels of fibrotic markers presented further
reduction, p38 activator reversely upregulated the pro-
tein expression, and promoted the collagen production
and deposition. The anti-fibrosis effect of ADSC-CM
was demonstrated to be achieved through inhibiting the
p38/MAPK signaling pathway in fibroblasts, cultured HS
tissues, and a mouse excisional wound. In summary, our
study might provide a novel therapeutic strategy for scar
treatment.
Methods
Patients and ethics approval
All human tissues including HS tissues, adjacent full-
thickness normal skin tissues, and adipose tissues were
obtained from patients (mean age 30 years) who under-
went surgical excision in Xijing Hospital (Xi’an, China).
Before surgery, all patients were informed of the purpose
and procedures of this study and agreed to offer their
excised tissues. Written consent was obtained from all
participants involved in this study. All protocols were
approved by the Ethics Committee of Xijing Hospital af-
filiated with Fourth Military Medical University.
Animals
Eight- to 10-week-old BALB/c mice were purchased
from the Experimental Animal Center of the Fourth
Military Medical University. The animal experimental
procedures were performed in strict accordance with
Experimental Animal Committee of the Fourth Military
Medical University (Xi’an, China).
Cell culture
Human-derived HSFs and NSFs were prepared as previ-
ously reported [17]. Briefly, the dermal portions were
minced and cultured by tissue block explant to isolate
HSFs and NSFs. Cells were incubated with Dulbecco’s
modified Eagle medium (DMEM; GIBCO, Grand Island,
NY, USA) supplemented with 10 % fetal calf serum
(FCS; GIBCO), 100 U/ml penicillin, and 100 μg/ml
streptomycin at 37 °C in a 5 % (v/v) CO2 humidified at-
mosphere. HSFs and NSFs between the third and fifth
passages were used for the following experiments. Cells
were seeded in six-well plates at a density of 2 × 105 cells
per well; 70–80 % confluent HSFs and NSFs were
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starved for 12–16 h in serum-free medium. The cells
were subjected to mRNA and protein analysis to assess
the expression of the fibrotic markers (Col1, Col3, and
α-SMA).
ADSCs were cultured as previously described [18]. Six
different human subcutaneous adipose tissue samples
were obtained after liposuction surgery (n = 6). BALB/c
mice were sacrificed and subcutaneous adipose tissue
samples were obtained (n = 6). Adipose tissues were
minced and incubated with 0.1 % collagenase I (Catalog
No.17100-017, Life Technologies, GIBCO) in phosphate-
buffered saline (PBS) with 2 mM calcium chloride for
1 h at 37 °C. The digested tissues were collected and fil-
tered through a 75-μm mesh, then centrifuged at 200 × g
for 5 min, and the supernatant was discarded. Cell pre-
cipitates were re-suspended in F12/DMEM (GIBCO)
containing 10 % FCS. When the third to fifth passages of
ADSCs achieved 80–90 % confluence, cells were starved
with serum-free medium for 24 h. Then, the supernatant
of ADSCs was collected, centrifuged at 200 × g for 5 min
and filtered using a 0.22-μm syringe filter, and finally
used as the ADSC-CM. Different concentrations of di-
luted ADSC-CM (10 %, 20 %, 40 %, 80 %) in mixed
medium (F12/DMEM:DMEM) were used in the follow-
ing experiments; an 80 % concentration of diluted
mouse ADSC-CM was prepared for the following
experiment.
Flow cytometric analysis
Cell surface marker expression was examined as follows:
Fluorochrome-conjugated anti-human CD14-FITC, CD31-
FITC, CD34-PE, CD44-PE, CD29-APC, CD73-PE, and
CD90-FITC antibodies and Fluorochrome-conjugated
anti-mouse CD29-FITC, CD31-FITC, CD44-PE, CD45-
PE, and CD106-FITC antibodies were purchased from
BD Pharmingen (San Diego, CA, USA) and used in ac-
cordance with the instructions of the manufacturer.
Non-specific staining was controlled by the use of
isotype-matched antibodies. ADSC suspensions were
incubated with the primary antibodies (1:50) for 30 min at
room temperature. After incubation, the cells were
washed twice with PBS and analyzed using a flow cyt-
ometer (BD FACSAria™ III system; BD Pharmingen).
Adipogenic and osteogenic differentiation
ADSCs at passages 3–5 were seeded in six-well plates
that were pre-coated with a 0.1 % gelatin solution
(Cyagen Bioscience, Inc., Guangzhou, China) at a
density of 105 cells per well and allowed to reach 80–
90 % confluence. Adipogenic differentiation was in-
duced by using a basic medium with 0.5 μmol/l dexa-
methasone, 0.5 mmol/l 3-isobutyl-1-methylxanthine,
0.1 mmol/l rosiglitazone, and 100 UI insulin for 2 weeks
(Cyagen Bioscience, Inc. HUXMD-90031); osteogenic
differentiation was achieved by using a basic medium con-
taining 0.1 μmol/l dexamethasone, 50 μmol/l ascorbic
acid, and 10 mmol/l β-glycerophosphate for 3 weeks
(Cyagen Bioscience, Inc. HUXMD-90021). Medium was
replaced every 3 days.
At the endpoint, cells were fixed with 4 % paraformal-
dehyde in PBS for 15 min at room temperature and
stained with specific oil red O and alizarin red S follow-
ing the manufacturers’ instructions, respectively, to as-
sess adipogenic and osteogenic differentiation. Specific-
stained ADSCs were documented under the Olympus
IX71 light microscope (Olympus, Tokyo, Japan).
Real-time quantitative polymerase chain reaction
(qRT-PCR)
qRT-PCR was performed as previously reported [19]. In
brief, total HSF and NSF RNA were extracted after 24 h
of incubation with or without different concentrations of
diluted ADSC-CM by using a RNA isolation kit (Takara,
Dalian, China). RNA purity was evaluated by calculating
the A260/A280 ratio, aiming for a value of 1.8–2.1. The
primer pairs (human) used for gene amplification from
the cDNA template were as follows: Col1: forward 5′-
GAGGGCAACAGCAGGTTCACTTA-3′ and reverse
5′-TCAGCACCACCGATGTCCA-3′; Col3: forward 5′-




hyde 3-phosphate dehydrogenase (GAPDH): forward 5′-
GCACCGTCAAGCTGAGAAC-3′ and reverse 5′-TGG
TGAAGACGCCAGTGGA-3′. The results from three
independent reactions were used to determine the rela-
tive expression levels of the target genes, which were
normalized against the expression level of the GAPDH
control.
Western blot analysis
Cells were harvested after 24 h of treatment with differ-
ent concentrations of diluted ADSC-CM or 1 h of treat-
ment with the p38 inhibitor SB203580 [20, 21] (10 μM
Beyotime, Shanghai, China) and/or 30 min of treatment
with the p38 activator anisomycin [22, 23] (25 μg/ml,
C14H19NO4 cell signaling technology, Inc.), washed in
PBS, and re-suspended in RIPA cell lysis solution
(Beyotime) supplemented with phenylmethylsulfonyl
fluoride (PMSF; Boster, Wuhan, China). The proteins
in cultured HS tissues were extracted by RIPA + PMSF
with a high-throughput tissue grinder. The protein con-
centration in each sample was determined by using a BCA
Protein Assay Kit (Beyotime). Western blot analysis was
performed as previously described [20]. Briefly, cell lysates
containing equal amounts of protein (50 μg) were sepa-
rated in 10 % sodium dodecyl sulfate polyacrylamide gels
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and transferred onto polyvinylidene fluoride membranes
at 100 V for 40–100 min (Millipore, Billerica, MA, USA).
The membranes were blocked with 5 % non-fat milk in
tris-buffered saline/0.5 % Tween-20 at room temperature
for 3–6 h, and then incubated at 4 °C overnight with
anti-Col1 (Rabbit, 1:1000; Abcam, Cambridge, UK),
anti-Col3 (Rabbit, 1:3000; Abcam), anti-α-SMA (Rabbit,
1:1000; Abcam), anti-p38MAPK (Rabbit, 1:1000; Cell
Signaling, Thermos Fisher Scientific Inc., USA), anti-
phospho-p38MAPK (Thr180/Tyr182) (Rabbit, 1:1000;
Cell Signaling), and anti-β-actin antibodies (Goat, 1:500;
Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The
membranes were then washed four times with tris-
buffered saline/0.5 % Tween-20 and incubated at 37 °C for
1 h with the corresponding horseradish peroxidase-
conjugated secondary antibodies (1:3000; Boster). The
membranes were then washed again four times with tris-
buffered saline/0.5 % Tween-20 and immunoreactive
traces were detected by using an ECL Kit (Millipore,
Billerica, MA, USA). The intensity of protein expression
on the membranes was analyzed by Image J software.
Immunocytofluorescence analysis
Fibroblasts cultured on coverslips were seeded in 12-
well plates and fixed in 4 % paraformaldehyde in PBS for
15 min at room temperature, following by washing with
PBS, three times per 5 min. Then, fibroblasts were incu-
bated with 0.1 % Triton X-100 in PBS for 30 min, fol-
lowing by washing with PBS, three times per 5 min
again. After blocking with1 % bovine serum albumin in
PBS for 1 h, the cells were incubated in BSA blocking
buffer containing primary antibodies-α-SMA (1:200;
Abcam), the cells were washed and then incubated in
secondary antibodies anti-rabbit (1:200; Life Technologies,
Carlsbad, CA, USA) for 1 h. Furthermore, fibroblasts were
incubated for 15 min with 4,6-diamidino-2-phenylindole
(DAPI; ZSGB, Beijing, China) for nuclear staining,
and fluorescence micrographs were obtained using an
Olympus FSX100 microscope.
Cultured HS tissues ex vivo
Human HS tissues that satisfied the following require-
ments were used in the study: 20–50 years; hypertrophic
scars had not faded within a year; the patients did
not administer any drugs before surgery; confirmation
of clinical diagnosis according to the appearance
(thickened, raised (>2 mm), red, hard, itchy, and the
relevant pathological diagnosis) (n = 6). Cultured HS
tissues ex vivo were performed as described previ-
ously [24–26]. Subcutaneous fat tissues were removed,
and HS tissues were cut into 10 × 10 mm sections
and cultured with DMEM/80 % ADSC-CM in the
presence of a p38 inhibitor (SB203580; 10 μM) and
activator (anisomycin; 25 μg/ml). Explants containing
complete epidermal and dermal layers were cultured
in an air liquid interface with the epidermal and kera-
tin layers side up and exposed to air. The medium
was changed every 3 days. HS tissues were harvested
after 7 days, and were fixed 4 % paraformaldehyde in
PBS for Masson’s trichrome staining or extracted for
total protein to measure the expression of p-p38,
Col1, Col3, and α-SMA.
BABL/c mice excisional model
BALB/c mice were randomly divided into two groups,
which were subcutaneously injected with either DMEM
or the equivalent mixed medium containing a 80 % con-
centration of ADSC-CM 1 day before the incision was
made (Day –1). Medium (1 ml) was injected subcutane-
ously at four points in the 1 cm × 1 cm region, with each
point receiving approximately the same volume. One
day later (Day 0) the skin was prepared with iodine solu-
tion. Full-thickness excisional wounds of 1 cm × 1 cm
were created using a template on the dorsal skin of
8- to 10-week-old BALB/c mice [27–29]. Three days
later (Day 3), experimental models were injected
again around the wound with the same volume as de-
scribed above. The injections were repeated after six
days (Day 6). Furthermore, to explore the anti-fibrosis
effect of ADSC-CM through the p38/MAPK signaling
pathway, we randomly divided BALB/c mice into six
groups (n = 6): DMEM, DMEM+ SB203580 (5 mg/kg)
[30], DMEM+ SB203580 + anisomycin (6.25 mg/kg) [31],
80 % ADSC-CM, 80 % ADSC-CM+ SB203580, 80 %
ADSC-CM+ SB203580 + anisomycin. Daily photos of the
wound were obtained for 2 weeks. The mice were then
sacrificed on Day 14 and the skin tissues of the wound
were harvested. The specimens were fixed in 4 % parafor-
maldehyde and sections were used for hematoxylin and
eosin (H&E), Masson’s trichrome staining, and immuno-
histochemistry staining.
Histopathology, immunohistochemistry, and Masson’s
trichrome staining analysis
The wound healing samples in vivo or cultured HS
tissues ex vivo were embedded in paraffin blocks and
cut into 4-μm thick tissue sections. One section was
used for routine H&E staining and another was used
for Masson’s trichrome staining analysis of collagen
fibers. For immunohistochemistry staining, sections
were dewaxed and endogenous peroxidase activity was
quenched with 3 % hydrogen peroxide for 15 min. The
sections were then blocked with normal goat serum
for 30 min to eliminate non-specific binding and in-
cubated overnight at 4 °C with primary antibodies
against Col1 or Col3 (1:100; Abcam). On the next day, the
sections were treated with a PV6000 Histostain™ kit
(ZSGB, Beijing, China) and stained with diaminobenzidine
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(ZSGB, Beijing, China). Finally, the sections were counter-
stained with hematoxylin. An isotype-matched IgG served
as the negative control for each immunostaining proced-
ure. Sections were analyzed and images acquired with
FSX100.
Statistical analysis
All data were analyzed using SPSS17.0 software; every
experiment was repeated at least three times, and the
data were presented as mean ± standard error of the
mean. Statistical analysis was performed by Student’s t
tests. P < 0.05 was considered statistically significant.
Results
Characterization of ADSCs
As reported previously [32, 33], human ADSCs presented
a typical fibroblast-like morphology (Fig. 1a), which dis-
played positive staining for the specific mesenchymal stem
cell surface markers CD29 (97.7 %), CD44 (99.1 %), CD73
(99.7 %), and CD90 (98.8 %), and negative staining for the
hematopoietic stem cell surface markers for CD31 (0.1 %),
CD34 (1.6 %), and monocyte antigen for CD14 (1.4 %)
(Fig. 1b). mADSCs presented a short fusiform morphology
(Additional file 1: Figure S1A), which displayed positive
staining for the specific MSC surface markers CD29
(99.09 %), CD44 (97.17 %), and CD106 (65.55 %), and
negative staining for the hematopoietic stem cell surface
markers for CD31 (1.06 %) and CD45 (5.26 %) (Additional
file 1: Figure S1B). Next, we examined the multi-potential
differentiation capacity of ADSCs by using adipogenic
and osteogenic assays. ADSCs were induced with adi-
pogenic medium for 2 weeks and showed an adipo-
genic phenotype by Oil Red O staining (Fig. 1c;
Additional file 1: Figure S1C). We also cultured ADSCs
with osteoblastogenic medium for 3 weeks and stained
them with Alizarin Red S to confirm the osteoblastogenic
Fig. 1 Characterization of human ADSCs. a Isolated human ADSCs presented a fibroblast-like morphology under light field microscope. b Flow
cytometry results show human ADSCs were positive for the MSC markers CD29 (97.7 %), CD44 (99.1 %), CD73 (99.7 %), and CD90 (98.8 %), and
were negative for the hematopoietic stem cell markers CD31 (0.1 %), CD34 (1.6 %), and monocyte cell antigen CD14 (1.4 %). c, d Adipogenic and
osteogenic differentiations were confirmed by Oil Red O and Alizarin Red S staining, respectively. Scale bars = 50 μm
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differentiation ability; the image indicated the presence of
calcium deposition (Fig. 1d; Additional file 1: Figure S1D).
The results demonstrated that the isolated ADSCs re-
vealed typical ADSCs characteristics.
ADSC-CM decreased the expression of Col1, Col3,
and α-SMA in HSFs
The deposition of collagen is characterized by overexpres-
sion of Col1 and Col3; increased contraction of myofibro-
blasts is marked by augmented α-SMA expression [34].
HSFs were stimulated with different concentrations of
ADSC-CM for 24 h; the mRNA and protein levels revealed
that ADSC-CM decreased the expression of Col1 and α-
SMA in a concentration-dependent manner in HSFs
(Fig. 2a–d). Furthermore, there were significant statistical
differences between the control group and 10 %, 20 %,
40 %, and 80 % concentrations of ADSC-CM group for
Col1 and α-SMA expression (Fig. 2e and g), accompanied
by the expression of Col3 between the control group and
20 %, 40 %, and 80 % concentrations of ADSC-CM (Fig. 2f).
There was no certain concentration-dependent change of
corresponding proteins in NSFs stimulated with ADSC-
CM (Additional file 2: Figure S3A–G). We further exam-
ined the expression of α-SMA by immunofluorescence
staining. The percentage of α-SMA-positive HSFs was sig-
nificantly lower in the 80 % concentration of the ADSC-
CM-treated group compared to the DMEM group. In
conclusion, our in vitro study indicated that ADSC-CM
exhibited an anti-fibrosis effect on the HSFs.
ADSC-CM suppressed collagen deposition in cultured HS
tissues
In the ex vivo experiment, after culture with DMEM or
an 80 % concentration of ADSC-CM for 7 days, HS tis-
sues sections were used for Masson’s trichrome staining
to assess the arrangement and morphology of collagen.
The result revealed the collagen in the 80 % concentra-
tion of ADSC-CM presented a thinner structure and or-
dered arrangement compared to the DMEM group
(tensed, excessive, and irregularly arranged collagen
bundles) (Fig. 3a) [35, 36]. Western blotting analysis of
Col1, Col3, and α-SMA indicated that the 80 % concen-
tration of ADSC-CM reduced the fibrosis of cultured HS
tissues (Fig. 3b). There were significantly statistical dif-
ferences between two groups (Fig. 3c–e). Thus, our ex
vivo study demonstrated that ADSC-CM might suppress
collagen deposition in HS tissues and ameliorate HS
fibrosis.
ADSC-CM reduced skin fibrosis in BABL/c mice excisional
model
A major limitation in the progress of scar management
is the lack of physiologically relevant human models to
explore the pathogenesis of hypertrophic scar formation.
Although many studies described pigs, mice, rabbits,
and other animals as models to investigate HS, the
wound healing process in these species presented signifi-
cant differences when compared with human scarring
[37]. Mouse models are used most extensively [38]. In
this study, we created 1 × 1 cm full-thickness cutaneous
wounds in the dorsal skin of BALB/c mice which were
treated by injecting ADSC-CM subcutaneously. Wound
areas were evaluated by daily images (Fig. 4a and b).
Specifically, H&E staining revealed faster wound healing
and less collagen deposition in the ADSC-CM treated
group, the histological score being assessed as described
previously [39] (Fig. 4c and d); Masson’s trichrome stain-
ing (Fig. 4e) and immunohistochemistry staining showed
that ADSC-CM significantly inhibited the expression of
Col1 and Col3 (Fig. 4f–h) in the dermis and presented
thinner and orderly arranged collagen. The in vivo ex-
periment demonstrated that ADSC-CM application was
a viable approach to significantly decrease the deposition
of collagen and prevent scar formation. The above re-
sults indicated that ADSC-CM maintained anti-fibrotic
properties in vivo. Furthermore, paracrine factors in
ADSC-CM might promote wound healing and decrease
scar formation.
ADSC-CM suppressed scar formation through the
inhibition of the p38/MAPK signaling pathway in HSFs in
vitro
As is well known, the p38/MAPK signaling pathway is
closely associated with inflammation and fibrosis [25];
we hypothesized that ADSC-CM might play an anti-
fibrosis role through the inhibition of the p38/MAPK
signaling pathway. HSFs were stimulated with mixed
medium (10 %, 20 %, 40 %, and 80 % concentrations of
ADSC-CM) after starvation for 24 h. We found the
protein level of p-p38 decreased in a concentration-
dependent manner (Fig. 5a). There were statistical differ-
ences between the DMEM and the 20 %, 40 %, and 80 %
concentrations of ADSC-CM treated groups (Fig. 5b).
However, the protein expression of p-p38 in NSFs
was not related to the concentration of ADSC-CM
(Additional file 2: Figure S3H–I). After stimulating
HSFs cultured in DMEM with SB203580 (10 μM was
confirmed by 7Sea-Cell Counting Kit; Additional file 3:
Figure S2A), on the premise of p-p38 reduction, the pro-
tein levels of Col1, Col3, and α-SMA decreased concomi-
tantly; there were statistical differences between the two
groups (Fig. 5c and d). Furthermore, we added SB203580
in a mixed medium (20 % and 80 % concentrations of
ADSC-CM), and the result indicated further reduction in
the protein level of p-p38 (Fig. 5e and f). The expression
level of Col1, Col3, and α-SMA presented a further reduc-
tion after adding a p38 inhibitor in mixed medium
(Fig. 5g). There were significant statistical differences
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between the control group and the p38 inhibitor group
(Fig. 5h–j). Moreover, when adding anisomycin (25 μg/ml
was confirmed by 7Sea-Cell Counting Kit; Additional
file 3: Figure S2B) to HSFs cultured with DMEM or
80 % concentration of ADSC-CM, the protein expres-
sion of Col1, Col3, and α-SMA reversely upregulated
(Fig. 5k). Therefore, we speculated that ADSC-CM
decreased collagen deposition and suppressed scar
formation through the p38/MAPK signaling pathway.
The anti-fibrosis effect of ADSC-CM was mediated by the
p38/MAPK signaling pathway in cultured HS tissues ex
vivo
Since we found that the anti-fibrosis effect of ADSC-CM
was contributed to by the p38/MAPK signaling pathway
in HSFs in vitro, a further experiment was carried out to
detect the role of p38/MAPK in cultured HS tissues ex
vivo. Firstly, the expression level of p-p38 decreased sig-
nificantly in HS tissues cultured with an 80 %
Fig. 2 The effect of ADSC-CM on the primary HSFs cultured in vitro. a–c qRT-PCR analysis for the mRNA levels of Col1, Col3, and α-SMA in HSFs
stimulated for 24 h with different concentrations of ADSC-CM (10 %, 20 %, 40 %, and 80 % concentrations of diluted conditioned medium); the
graph represents the expression of Col1, Col3, and α-SMA relative to that of GAPDH. d–g Immunoblot analysis for the protein expression of Col1,
Col3, and α-SMA in HSFs stimulated for 24 h with different concentrations of ADSC-CM (10 %, 20 %, 40 % and 80 % concentrations of diluted
conditioned medium); the graph shows the relative band density to β-actin. Every experiment was repeated at least three times. The data are
shown as mean ± SEM (*P < 0.05; **P < 0.01). h Immunofluorescence staining of α-SMA expression in HSFs stimulated with 80 % concentration of
ADSC-CM for 24 h. Scale bars = 50 μm. ADSC-CM adipose tissue-derived stem cell-conditioned medium, Col1 collagen I, Col3 collagen III, DAPI 4,
6-diamidino-2-phenylindole, DMEM Dulbecco’s modified Eagle medium, SMA smooth muscle actin
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concentration of ADSC-CM compared to DMEM (Fig. 6a
and b). To verify the function of anisomycin, we upregu-
lated the expression of p-p38 by adding anisomycin in
DMEM or 80 % concentration of ADSC-CM, and the re-
lated fibrotic proteins presented a further increase
(Fig. 6c). Furthermore, the protein levels of Col1, Col3,
and α-SMA in HS tissues cultured with DMEM
(Fig. 6d–h) or an 80 % concentration of ADSC-CM
(Fig. 6i–m) in the presence of the p38 inhibitor repre-
sented a significant reduction compared to the control
Fig. 4 ADSC-CM promoted wound healing and reduced scar formation. a, b The morphology of incisions were observed at different time points
after injecting subcutaneously with DMEM and 80 % concentration of ADSC-CM. Relative wound areas are shown by histogram. c, d The
histopathological change of wound healing was shown by H&E staining between DMEM and 80 % concentration of ADSC-CM group. The
histologic scores were assessed by histogram. Scale bars = 400 μm. e Masson’s trichrome staining labeled collagen in wound healing tissues of mice
treated with DMEM and 80 % concentration of ADSC-CM. f–h Immunohistochemistry staining of Col1 and Col3 in wound healing tissues of mice treated
with DMEM and 80 % concentration of ADSC-CM. Relative density of collagen was shown by histogram. Scale bars= 50 μm (n= 6 mice per group).
ADSC-CM adipose tissue-derived stem cell-conditioned medium, Col1 collagen I, Col3 collagen III, D days, DMEM Dulbecco’s modified Eagle medium
Fig. 3 The effect of ADSC-CM on cultured HS tissues ex vivo. a The histology and morphology structure of HS tissues were measured by Masson’s
trichrome staining for labeling collagen fibers blue after stimulation with 80 % concentration of ADSC-CM or DMEM for 7 days. Scale bar = 100 μm or
50 μm as indicated. b–e Western blotting analysis for Col1, Col3, and α-SMA in HS tissues cultured with an 80 % concentration of ADSC-CM or DMEM.
Quantitative analysis is shown by histogram. Every experiment was repeated three times at least. The data are shown as mean ± SEM
(*P < 0.05; **P < 0.01). ADSC-CM adipose tissue-derived stem cell-conditioned medium, Col1 collagen I, Col3 collagen III, DMEM Dulbecco’s
modified Eagle medium, SMA smooth muscle actin
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group. We added anisomycin to cultured HS tissues in
the presence of the p38 inhibitor. The protein expression
of p-p38 was used to confirm the effect of the p38 activa-
tor. Anisomycin could reversely upregulate the levels of
Col1, Col3, and α-SMA, and there were statistical differ-
ences between the p38 inhibitor group and the other two
groups. Moreover, the collagen in the p38 inhibitor-treated
group represented a more ordered arrangement and thin-
ner structure; on the contrary, the collagen stimulated with
anisomycin demonstrated a more disordered, denser, ex-
cessive, and irregularly arranged structure (Fig. 6n).
The anti-fibrosis effect of ADSC-CM was manifested
through the p38/MAPK signaling pathway in BALB/c
mouse excisional models in vivo
To demonstrate the effect of p38 on wound healing and
scar formation, excisional models were established in
BALB/c mice, which were treated with intradermal in-
jections of DMEM or 80 % ADSC-CM with SB203580/
anisomycin. The pictures of the wound healing process
are shown in Fig. 7a. Relative wound areas were analyzed
by Image Pro Plus software (Fig. 7b); SB203580 could
promote wound healing, whereas the application of ani-
somycin inhibited the beneficial effects. The samples
were harvested 2 weeks later. H&E and Masson’s tri-
chrome staining were used to measure the structure and
arrangement of collagen. As shown in Fig. 7c and e,
treatment with SB203580 presented more ordered and
thinner collagen fibers compared to the control group
(DMEM or 80 % ADSC-CM, respectively), which resulted
in less inflammatory cellular infiltration and collagen de-
position; on the contrary, anisomycin reversed the anti-
fibrosis effects of ADSC-CM and revealed a more irregu-
larly arranged structure and denser collagen fibers. There
Fig. 5 ADSC-CM decreased scar fibrosis through the p38/MAPK signaling pathway in HSFs in vitro. a, b To explore the underlying mechanism of the
anti-fibrotic effect of ADSC-CM, the protein level p-p38 was measured by Western blotting in primary HSFs in different concentrations of ADSC-CM
(10 %, 20 %, 40 %, and 80 % concentrations of diluted conditioned medium); graph shows the relative band density to total p38. c, d The protein level
of p-p38, Col1, Col3, and α-SMA in HSFs stimulated with DMEM in the presence of SB203580. e, f Western blotting analysis for p-p38 in primary HSFs
stimulated with 20 % and 80 % concentrations of ADSC-CM in the presence of SB203580; the histogram presents the p-p38/p38 ratio. g–j Protein
levels of Col1, Col3, and α-SMA stimulated with 20 % and 80 % concentrations of ADSC-CM in the presence of SB203580; graph shows the relative
band density to β-actin. k Immunoblot analysis of p-p38, Col1, Col3, and α-SMA when stimulated with SB203580 and/or anisomycin. The data are
shown as mean ± SEM from three independent experiments (*P < 0.05; **P < 0.01). A anisomycin, ADSC-CM adipose tissue-derived stem
cell-conditioned medium, Col1 collagen I, Col3 collagen III, DMEM Dulbecco’s modified Eagle medium, S SB203580, SMA smooth muscle actin
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Fig. 6 ADSC-CM decreased the expression of collagen and improved the structure and arrangement of collagen through the p38/MAPK
signaling pathway in cultured hypertrophic scars tissues ex vivo. a, b Immunoblot analysis for the expression of p-p38 stimulated with DMEM or
80 % concentration of ADSC-CM for 7 days. c The protein levels of p-p38, Col1, Col3, and α-SMA in hypertrophic scar tissues cultured with DMEM
or 80 % concentration of ADSC-CM including anisomycin. d–h To verify the role of the p38/MAPK signaling pathway underlying the anti-fibrosis
effect of ADSC-CM, SB203580 and/or anisomycin were added into the medium of DMEM cultured scar tissues. The protein expression of Col1,
Col3, and α-SMA are shown. Graphs show the relative band density to β-actin. i–m Western blotting analysis for Col1, Col3, and α-SMA in HS
tissues cultured with 80 % concentration of ADSC-CM in the presence of p38 inhibitor and/or activator. Graphs show the relative band density to
β-actin. Quantitative analysis is shown by histogram. n The structure and arrangement of collagen fibers by Masson’s trichrome staining in DMEM
and 80 % ADSC-CM cultured HS tissues in the presence of p38 inhibitor and/or activator. Scale bars = 50 μm. *P < 0.05; **P < 0.01. A anisomycin,
ADSC-CM adipose tissue-derived stem cell-conditioned medium, Col1 collagen I, Col3 collagen III, DMEM Dulbecco’s modified Eagle medium, S
SB203580, SMA smooth muscle actin
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Fig. 7 ADSC-CM decreased scar formation through the p38/MAPK signaling pathway in mouse excisional models. a, b The wound healing
process in BALB/c mice injected intradermally with DMEM or an 80 % concentration of ADSC-CM in the presence of p38 inhibitor and/or activator
at different time points. Relative distances (pixels) were analyzed by Image Pro Plus software and are shown as a histogram. c, d H&E staining
showed less inflammatory cellular infiltration and collagen production in the p38 inhibitor group; anisomycin reversed the function and led to
more inflammatory cellular infiltration and collagen synthesis. The histologic scores are shown by a histogram. Scale bars = 400 μm. e P38 inhibitor
groups showed more ordered and thinner collagen fibers by Masson's trichrome staining; on the contrary, anisomycin represented more
disordered and denser collagen fibers. Scale bars = 50 μm. *P < 0.05. A anisomycin, CM conditioned medium, D days, DMEM (D) Dulbecco’s
modified Eagle medium, S SB203580
Li et al. Stem Cell Research & Therapy  (2016) 7:102 Page 11 of 16
were statistical differences between the p38 inhibitor
group and the other two groups for the histologic score
(Fig. 7d). Furthermore, we detected less positive expres-
sion of Col1 and Col3 in mice injected intradermally with
the p38 inhibitor as measured by immunohistochemistry
staining; after adding anisomycin, the protein levels of
Col1 and Col3 increased significantly, showing that
anisomycin could upregulate the levels of collagen (Fig. 8a
and b). The relative density of collagen was measured by
Image Pro Plus software and was revealed by histogram;
there were statistical differences between the p38 inhibitor
group and the other groups (Fig. 8c and d).
Fig. 8 a, b SB203580 group revealed less positive expression of Col1 and Col3 as measured by immunohistochemistry staining; anisomycin
upregulated the positive expression of Col1 and Col3. c, d Relative density of collagen was analyzed by Image Pro Plus software and revealed by
histogram. Scale bars = 50 μm. *P < 0.05; **P < 0.01. A anisomycin, CM conditioned medium, Col1 collagen I, Col3 collagen III, DMEM (D) Dulbecco’s
modified Eagle medium, S SB203580
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Discussion
This study provides the following major findings. First,
in opposite to opinion about the effect of ADSC-CM
promoting fibrosis, we identified that ADSC-CM could
exert an anti-fibrotic ability via the specific concentra-
tions of diluted conditioned medium. Second, we dem-
onstrated that the possible underlying mechanism for
the effect of ADSC-CM on HS might be reflected
through the inhibition of the p38/MAPK signaling path-
way. These points indicate that the anti-fibrotic property
of ADSC-CM via that p38/MAPK signaling pathway
may serve as a new therapeutic target.
HS represent the main clinical challenge to burn and
plastic surgeons owing to their high incidence in skin in-
jury patients and the lack of an effective treatment strat-
egy [40–42]. Fibrosis is a common response caused by
chronic organ injury, with excessive deposition of ECM
components mainly composed of collagen fibers and
various other fibrous proteins [43]. In HS tissues, fibro-
blasts and myofibroblasts in the dermis are thought to
be the most dominant cells [44], and fibroblasts are acti-
vated and trans-differentiated into myofibroblasts during
the progression of HS. Myofibroblasts, which produce
excessive amounts of collagen and ECM proteins, have a
contractile phenotype and are involved in narrowing the
margin of the wounds and accelerating the re-
epithelialization by contraction [45].
Human ADSCs exhibit fibroblastic and spindle-shaped
morphology, and co-expressed several mesenchymal
markers such as CD29, CD44, CD73, and CD90. Mouse
ADSCs revealed a short fusiform morphology and
expressed some mesenchymal markers such as CD29,
CD44, and CD106. Similar to the previous study, it was
confirmed that ADSCs could be also trans-differentiated
into adipocytes and osteoblasts, which demonstrated
their potential multi-lineage differentiation abilities. The
application of ADSC-derived paracrine molecules as a
possible therapeutic approach to HS is of enormous
interest.
Recently, the influence of ADSC therapy on cardiac re-
modeling has been reported by using the acute myocar-
dial infarction mouse model, with an observed smaller
infarct size and less scar formation [46]. ADSCs also
presented an anti-fibrotic effect in muscle injury [47].
The therapeutic effects of ADSC transplantation on peri-
toneal fibrosis are facilitated by suppressing epithelial-
mesenchyme transition, and modulating inflammation
and angiogenesis during the early phase of tissue repair
[48]. Further studies have revealed ADSCs could down-
regulate pulmonary fibrosis induced by repetitive bleo-
mycin administration [49]. Remarkably, our in vitro
study revealed ADSC-CM reduced the expression of
Col1, Col3 (the main collagen types of skin [50]), and α-
SMA, suggesting that ADSC-CM could decrease the
deposition of collagen and the trans-differentiation of fi-
broblasts into myofibroblasts which was characterized
by less positive cells for α-SMA. We subsequently tested
the anti-fibrotic effect of ADSC-CM in cultured HS tis-
sues ex vivo; the structure of collagen presented a thin-
ner and more orderly arranged structure, and the
protein levels of fibrotic-related markers also decreased,
which was in accordance with the in vitro experiment.
For in vivo study, we performed the excisional model on
the dorsal skin of BALB/c mice, and the result revealed
that the injection of ADSC-CM subcutaneously led to
faster wound healing, less collagen deposition, thinner
collagen fibers, and a more orderly arranged ECM as
measured by histopathology analysis. Taken together,
among in vitro, ex vivo and in vivo studies, ADSC-CM
was demonstrated to possess an ability for anti-fibrosis,
which might provide a promising strategy for clinical
treatment.
However, there are contrary opinions, demonstrating
that ADSC-CM can promote fibrosis. Lee et al. found
that paracrine factors released by ADSCs increased the
proliferation of dermal fibroblasts [51]. Kim et al. dem-
onstrated that ADSCs stimulated fibroblast proliferation
and migration, and Col1 secretion, in an in vitro wound
healing model [52]. The discrepancy might possibly be
explained by the fact that the ADSC-CM tended to pro-
mote collagen synthesis in untreated fibroblasts; it was
considered that ADSC-CM promoted fibroblast collagen
synthesis under normal conditions, whereas they inhib-
ited the process in pro-fibrotic conditions [53]. The con-
trary opinion may also be largely attributed to the
growth conditions of ADSCs and fibroblasts, and differ-
ent concentrations of ADSC-CM in the mixed medium.
It has been reported that HS are characterized by
microvascular dysplasia with infiltration of inflammatory
cells. Accumulating evidence suggests that there is a link
between inflammation and fibrosis. Recent reports sug-
gest that MSCs attenuate wound inflammation and
inhibit fibrosis [54–56]. The effect of ADSCs on sup-
pressing fibroblast proliferation and scar formation in-
duced by inflammatory cytokines probably were caused
by paracrine actions. The factors that ADSCs secrete
could suppress excess synthesis of collagen and accel-
erate the process of collagen remodeling in normal
arrangements.
P38/MAPK pathways, a class of highly conserved
serine/threonine protein kinase within the cytoplasm
[15], are closely related to the inflammatory response.
P38/MAPK is also a positive regulator of collagen
synthesis in dermal fibroblasts, which promotes ECM
production. P38/MAPK is involved in the process of
cell trans-differentiation, which is activated in HS fi-
brosis through the TGFβ1/Smad2/3 pathway [57]. We
hypothesized the anti-fibrotic effect of ADSC-CM
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might be achieved via the p38/MAPK pathway and
then detected the expression of p-p38 in HSFs stimu-
lated with ADSC-CM. The result demonstrated that
the reduction in p-p38 level was associated with the
anti-fibrotic effect of ADSC-CM, and a p38 inhibitor
further supported this action. SB203580 can reduce
the extracellular matrix protein production in keloid
fibroblasts by inhibiting insulin-like growth factor-I-
induced transforming growth factor-β1 [58], and
SB203580 treatment results in a significantly smaller
scar size which subsequently improves cardiac func-
tion [59]. Our study also demonstrated that SB303580
decreased scar fibrosis and promoted wound healing—the
protein levels of Col1, Col3, and α-SMA presented a
decreasing trend in HSFs. The histopathological ana-
lysis in the p38 inhibitor group revealed less inflam-
matory cellular infiltration and decreased collagen
secretion, synthesis, and deposition. The histological
analysis revealed more ordered and thinner collagen.
Besides, there was less positive protein expression of
collagen in the p38 inhibitor group. Anisomycin, a
p38/MAPK activator, mimicks the effect of TGF-β1,
which further inhibits wound healing and promotes
scar formation [60]; on the other hand, anisomycin
can delay wound healing and accelerate the fibrosis
process by promoting inflammation [61]. In this
study, after adding anisomycin in ADSC-CM treated
fibroblasts and cultured HS tissues, the protein ex-
pression of Col1, Col3, and α-SMA reversely upregu-
lated. Masson’s trichrome staining presented denser,
more disordered, excessive, and irregularly arranged
collagen. The mice intradermally injected with aniso-
mycin presented delayed wound healing, more inflam-
matory cellular infiltration, and increased scar formation
and collagen deposition. Anisomycin-treated mice also
showed enhanced expression of Col1 and Col3. From
the above, our study suggests that the inhibition of
the p38/MAPK pathway played an important role in
the amelioration of HS fibrosis mediated by ADSC-
CM. However, the underlying mechanism still needs
further exploration.
Conclusions
This study demonstrates that ADSC-CM, the condi-
tioned medium of ADSCs, significantly decreased col-
lagen expression and deposition, and inhibited the
trans-differentiation of fibroblasts into myofibroblasts.
In addition, the study indicated that ADSC-CM sup-
pressed HS fibrosis through regulating the p38/MAPK
signaling pathway. Our data provide a potential thera-
peutic strategy for HS treatment, and the special fac-
tors in ADSC-CM which exert the anti-fibrotic function
need to be further elucidated, and the underlying mechan-
ism still needs to be explored.
Additional files
Additional file 1: Figure S1. Characterization of mouse adipose-derived
mesenchymal stem cells (mADSCs) in vitro. (A) Isolated mADSCs presented
a short fusiform morphology under light field microscope. (B) Flow
cytometry results show that mADSCs were positive for the mesenchymal
stem cell markers CD29 (99.09 %), CD44 (97.17 %), and CD106 (65.55 %), but
were negative for the hematopoietic stem cell markers CD31 (1.06 %) and
CD45 (5.26 %). (C–D) Oil Red O and Alizarin Red S staining were used to
confirm adipogenic and osteogenic differentiations, respectively. Scale
bar = 50 μm. (TIF 5839 kb)
Additional file 2: Figure S3. The effect of ADSC-CM on the primary
NS-derived fibroblasts in vitro. (A-C) qRT-PCR analysis for the mRNA levels
of Col1, Col3, and α-SMA in NSFs stimulated with different concentrations
of ADSC-CM (10 %, 20 %, 40 %, 80 %) for 24 h; graph representeds the
expression of Col1, Col3, and α-SMA relative to that of GAPDH. (D–G)
Immunoblot analysis for the protein expression of Col1, Col3, and α-SMA
in NSFs stimulated with different concentrations of ADSC-CM (10 %,
20 %, 40 %, 80 %) for 24 h; graph shows the relative band density
to β-actin. (H, I) Immunoblot analysis for the expression of p-p38
stimulated for 1 h with different concentrations of ADSC-CM (10 %,
20 %, 40 %, 80 %). Every experiment was repeated three times at
least. The data are shown as mean ± SEM from three independent
experiments (*P < 0.05; **P < 0.01). (TIF 1346 kb)
Additional file 3: Figure S2. The confirmation of the concentration of
p38 inhibitor (SB203580) and p38 activator (anisomycin) (A, B). 7Sea-Cell
Counting Kit was used to detect the absorbance in different concentrations
of SB203580 and anisomycin to confirm the suitable concentration.
(TIF 488 kb)
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